Immune organ tertiary lymphoid structures (TLSs) as a therapeutic strategy for solid tumors 2247222
The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)
DOI: 10.1093/jimmun/vkag141.061 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Sudip Paudel und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Tertiary lymphoid structures (TLSs) are linked to better patient outcomes and enhanced immunity in some cancers (e.g. ovarian, lung). TLSs support the reprogramming of immune system to attack the tumor and retain a long-term memory. We employed our previously published TLS-on-chip microfluidic device (TOD) and in vivo murine models to test a novel therapeutic formulation that involves engineering in situ TLSs to combat solid tumors. This formulation aims to generate effector T cells, memory B cells, and tumor-antigen-specific antibodies locally.
Methods
We integrated different cancer cell lines expressing varying levels of PD-L1/PD-L2 with healthy and cancer patients PBMCs in the TODs to quantify TLS formation, lymphocyte activation, and cancer cell killing. Based on the TOD’s composition, we defined a cellularized extracellular matrix gel to create TLS in vivo. To investigate the in vivo efficacy of this gel, we injected it peritumorally in a lung cancer cell line-derived xenograft (CDX) and a syngeneic model to monitor TLS formation and survival benefit measured by tumor volume reduction.
Results
TOD studies showed that with “hot” cancer cell lines (high PD-L1/PD-L2), our formulation induced TLS formation leading to a robust cytokine response, B cell activation, anti-tumor CD8+ T cell activity, and cancer cell death. In contrast, “cold” tumor cell lines suppressed TLS formation and the immune response. Peri-tumoral administration of the formulation successfully generated TLSs at the tumor site in a lung cancer CDX model in NSG mice. Intriguingly, they syngeneic lung cancer model showed reduced tumor volume and improved survival in the treated cohort.
Conclusion
Our findings demonstrate the feasibility of an injectable TLS therapeutic to overcome tumor-mediated immune suppression and generate a potent anti-tumor immune response. This approach has the potential to improve patient survival in challenging solid tumors. Further preclinical development of this promising therapy is ongoing. Funding Source ARPA-H Sprint for Women’s Health award Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Zitieren
APA
Paudel, S., De, C., Sarro, J., Barck, L., Isaacs, A., Prabhala, P., Zhai, Y., Ingber, D., & Goyal, G. (2026). Immune organ tertiary lymphoid structures (TLSs) as a therapeutic strategy for solid tumors 2247222. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.061
Vancouver
Paudel S, De C, Sarro J, Barck L, Isaacs A, Prabhala P, et al. Immune organ tertiary lymphoid structures (TLSs) as a therapeutic strategy for solid tumors 2247222. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.061
BibTeX
@article{Paudel2026,
author = {Paudel, Sudip and De, Chandrav and Sarro, Jessica and Barck, Lucas and Isaacs, Abdul and Prabhala, Pranav and Zhai, Yunhao and Ingber, Donald and Goyal, Girija},
title = {Immune organ tertiary lymphoid structures (TLSs) as a therapeutic strategy for solid tumors 2247222},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {Supplement_1},
doi = {10.1093/jimmun/vkag141.061}
}
EUVIMED